Cited by 50COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Dermatological and COVID-19 studies

COVID-19 and the digestive system: A comprehensive review

Open access
Wang, Ming-Ke, Yue, Hai-Yan, Cai, Jin, Zhai, Yu-Jia, Peng, Jian-Hui, Hui, Ju-Fen, Hou, Deng-Yong, Li, Wei-Peng +1 more·2021·World Journal of Clinical Cases

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is spreading at an alarming rate, and it has created an unprecedented health emergency threatening tens of millions of people worldwide. Previous studies have indicated that SARS-CoV-2 ribonucleic acid could be detected in the feces of patients even after smear-negative respiratory samples. However, demonstration of confirmed fecal-oral transmission has been difficult. Clinical studies have shown an incidence rate of gastrointestinal (GI) symptoms ranging from 2% to 79.1% in patients with COVID-19. They may precede or accompany respiratory symptoms. The most common GI symptoms included nausea, diarrhea, and abdominal pain. In addition, some patients also had liver injury, pancreatic damage, and even acute mesenteric ischemia/thrombosis. Although the incidence rates reported in different centers were quite different, the digestive system was the clinical component of the COVID-19 section. Studies have shown that angiotensin-converting enzyme 2, the receptor of SARS-CoV-2, was not only expressed in the lungs, but also in the upper esophagus, small intestine, liver, and colon. The possible mechanism of GI symptoms in COVID-19 patients may include direct viral invasion into target cells, dysregulation of angiotensin-converting enzyme 2, immune-mediated tissue injury, and gut dysbiosis caused by microbiota. Additionally, numerous experiences, guidelines, recommendations, and position statements were published or released by different organizations and societies worldwide to optimize the management practice of outpatients, inpatients, and endoscopy in the era of COVID-19. In this review, based on our previous work and relevant literature, we mainly discuss potential fecal-oral transmission, GI manifestations, abdominal imaging findings, relevant pathophysiological mechanisms, and infection control and prevention measures in the time of COVID-19.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.12998/wjcc.v9.i16.3796

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several studies showed the important role of IL-1 in endothelial dysfunction, inflammation, and thrombi formation in COVID-19 patients by stimulating the production of Thromboxane A2 (TxA2) and thromboxane B2 (TxB2).

    “Several studies showed the important role of Il-1 in endothelial dysfunction, inflammation, and thrombi formation in COVID-19 patients by stimulating the production of Thromboxane A2 (TxA2) and thromboxane B2 (TxB2).”

    From Acute mesenteric ischemia in COVID-19 patients (2021) · cites this paper as [80]

  • These findings may justify the recommendation for an IL-1 receptor antagonist (IL-1Ra) which can prevent hemodynamic changes, septic shock, organ inflammation, and vascular thrombosis in severe forms of COVID-19 patients.

    “These findings may justify the recommendation for an IL-1 receptor antagonist (IL-1Ra) which can prevent hemodynamic changes, septic shock, organ inflammation, and vascular thrombosis in severe forms of COVID-19 patients [80,81,82].”

    From Acute mesenteric ischemia in COVID-19 patients (2021) · cites this paper as [80]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 134 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Wang, M.-K., Yue, H.-Y., Cai, J., Zhai, Y.-J., Peng, J.-H., Hui, J.-F., Hou, D.-Y., Li, W.-P., & Yang, J.-S.
Affiliations
Second Military Medical University (CN)
Venue
World Journal of Clinical Cases
Published
2021-06-06
Volume
9
Issue
16
Pages
3796-3813
ISSN
2307-8960 (ISSN-L)
OpenAlex
W3162527482
Cited by
50
References
134
Citations by year
2026: 2 · 2025: 2 · 2024: 11 · 2023: 11 · 2022: 19 · 2021: 5
FWCI
1.35
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • World Journal of Clinical Cases (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
  • Health Sciences › Medicine › Dermatology › Dermatological and COVID-19 studies
Keywords
COVID-19 pandemic, SARS-CoV-2, gastrointestinal symptoms, fecal-oral transmission, ACE2 receptor, gut dysbiosis, liver injury, acute mesenteric ischemia, abdominal imaging findings, infection control, diarrhea, nausea

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review